news aggregator

Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, announced that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer"...

Treatments modelled on the cancer drug Gleevec could potentially prevent the formation of amyloid plaques - one of the major hallmarks of Alzheimer's disease according to a study. Treatments modelled on the cancer drug Gleevec could potentially prevent the formation of amyloid plaques - one of the major hallmarks of Alzheimer's disease according to a study published in the journal Nature...

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept...

Today, at the Engineering in Medicine and Biology Conference (EMBC) in Buenos Aires (Argentina), imec and its project partners have announced the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims to develop an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells (CTCs and DTCs) in blood...

A "game-changing" technique using near infrared light enables scientists to look deeper into the guts of cells, potentially opening up a new frontier in the fights against cancer and many other diseases. University of Central Florida chemists, led by Professor Kevin Belfield, used near infrared light and fluorescent dye to take pictures of cells and tumors deep within tissue...

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory...

A new study from the Center for Interdisciplinary Chronobiological Research at the University of Haifa has found an additional link between Light At Night (LAN) and cancer. This research joins a series of earlier studies carried out at the University of Haifa that also established the correlation...

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecules that target P2X3 receptors, announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist significantly prevented and reversed bone cancer pain behavior in comparison to vehicle controls...

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory...

A new UK study that followed a large number of people found that those who took 10 or more prescriptions for oral bisphosphonates, a group of drugs commonly used to treat the bone disease osteoporosis, were at higher risk of developing oesophageal cancer...

A cell devotes a significant amount of effort to maintaining the stability of its genome, preventing the sorts of chromosomal rearrangements characteristic of many cancers. Assays that measure the rate of gross chromosomal rearrangements (GCRs) are needed in order to understand the individual genes and the different pathways that suppress genomic instability...

With temperatures set to plummet below freezing across the UK this week, leading cancer charity Macmillan Cancer Support is warning that keeping warm will be even harder for cancer patients undergoing treatment, as they are already twice as likely to fall into fuel poverty as the general population 1 ...

Responding to the decision by the National Institute for Health and Clinical Excellence (NICE) not to recommend sorafenib (Nexavar®) as a treatment for advanced liver cancer, Mike Hobday, Head of Campaigns at Macmillan Cancer Support, said: 'We are extremely disappointed that NICE has decided not to recommend sorafenib as a treatment for people with advanced liver cancer...

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma...

Lung cancer is the leading cause of cancer deaths worldwide, and the prognosis is generally poor, even if surgery is successful. Furthermore, the incidence of one type of lung cancer, adenocarcinoma, has been increasing in recent years...

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all...

One of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques...

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute (TGen) published in the journal Molecular Cancer...

When it comes to the mechanics of the human immune system, we are all more alike than previously thought, according to a new study by scientists at Fred Hutchinson Cancer Research Center. This finding has significant implications for developing new ways to detect, diagnose and treat cancer and diseases of the immune system, according to Harlan Robins, Ph.D...